NCT05858710View on ClinicalTrials.gov

Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

May 28, 2025

Conditions
Sarcoma, Soft Tissue
Interventions
DRUG

DPPG2-TSL-DOX

DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.

DRUG

Dexrazoxane

For cardioprotection of participants.

Trial Locations (2)

13125

Helios Klinikum Berlin-Buch GmbH, Berlin

81377

Klinikum der Universität München (KUM) Campus Großhadern, Munich

All Listed Sponsors
lead

Thermosome GmbH

INDUSTRY